Deep Dive Into ANI Prescribed drugs Inventory: Analyst Views (6 Rankings)

Over the last three months, 6 analysts shared their evaluations of ANI Prescribed drugs (NASDAQ:ANIP), revealing various outlooks from bullish to bearish.

The desk beneath offers a snapshot of their latest scores, showcasing how sentiments have developed over the previous 30 days and evaluating them to the previous months.

The 12-month worth targets assessed by analysts reveal additional insights, that includes a mean goal of $87.5, a excessive estimate of $94.00, and a low estimate of $80.00. This present common has decreased by 2.23% from the earlier common worth goal of $89.50.

Decoding Analyst Rankings: A Detailed Look

The evaluation of latest analyst actions sheds mild on the notion of ANI Prescribed drugs by monetary specialists. The next abstract presents key analysts, their latest evaluations, and changes to scores and worth targets.

| Analyst | Analyst Agency | Motion Taken | Score |Present Value Goal| Prior Value Goal |
|——————–|——————–|—————|—————|——————–|——————–|
|Vamil Divan |Guggenheim |Maintains |Purchase | $86.00|$86.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |
|Glen Santangelo |Jefferies |Proclaims |Purchase | $80.00|- |
|Ekaterina Knyazkova |JP Morgan |Proclaims |Chubby | $85.00|- |
|Vamil Divan |Guggenheim |Raises |Purchase | $86.00|$84.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |

Key Insights:

• Motion Taken: Analysts adapt their suggestions to altering market situations and firm efficiency. Whether or not they ‘Preserve’, ‘Elevate’ or ‘Decrease’ their stance, it displays their response to latest developments associated to ANI Prescribed drugs. This info offers a snapshot of how analysts understand the present state of the corporate.
• Score: Analyzing tendencies, analysts supply qualitative evaluations, starting from ‘Outperform’ to ‘Underperform’. These scores convey expectations for the relative efficiency of ANI Prescribed drugs in comparison with the broader market.
• Value Targets: Analysts predict actions in worth targets, providing estimates for ANI Prescribed drugs’s future worth. Inspecting the present and prior targets presents insights into analysts’ evolving expectations.

Navigating by these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of ANI Prescribed drugs’s market standing. Keep knowledgeable and make data-driven choices with our Rankings Desk.

Stay up to date on ANI Pharmaceuticals analyst ratings.

If you’re fascinated by following small-capstock newsand efficiency you can start by tracking it here.

Discovering ANI Prescribed drugs: A Nearer Look

ANI Prescribed drugs Inc develops, manufactures, and markets generic prescription prescribed drugs. It manufactures liquid, powder, and oral solid-dose merchandise. Its areas of product growth embrace narcotics, oncolytics, hormones and steroids, and complicated formulations involving extended-release and mixture merchandise. A few of its generic merchandise embrace Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The corporate operates in two segments which embrace Uncommon Illnesses and Manufacturers, Generics, and Others. Its geographical segments are the USA and Canada, of which the vast majority of its income comes from the USA.

ANI Prescribed drugs’s Financial Influence: An Evaluation

Market Capitalization: With restricted market capitalization, the corporate is positioned beneath business averages. This displays a smaller scale relative to friends.

Income Progress: ANI Prescribed drugs’s exceptional efficiency in 3M is obvious. As of 31 December, 2024, the corporate achieved a powerful income development charge of 44.75%. This signifies a considerable improve within the firm’s top-line earnings. As in comparison with its friends, the income development lags behind its business friends. The corporate achieved a development charge decrease than the typical amongst friends in Well being Care sector.

Internet Margin: ANI Prescribed drugs’s web margin is spectacular, surpassing business averages. With a web margin of -5.61%, the corporate demonstrates robust profitability and efficient value administration.

Return on Fairness (ROE): The corporate’s ROE is a standout performer, exceeding business averages. With a powerful ROE of -2.64%, the corporate showcases efficient utilization of fairness capital.

Return on Property (ROA): The corporate’s ROA is a standout performer, exceeding business averages. With a powerful ROA of -0.83%, the corporate showcases efficient utilization of property.

Debt Administration: With a below-average debt-to-equity ratio of 1.55, ANI Prescribed drugs adopts a prudent monetary technique, indicating a balanced strategy to debt administration.

The Core of Analyst Rankings: What Each Investor Ought to Know

Benzinga tracks 150 analyst companies and experiences on their inventory expectations. Analysts sometimes arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, normally the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.

Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their scores on shares. Analysts sometimes charge every inventory as soon as per quarter or each time the corporate has a significant replace.

Analysts might complement their scores with predictions for metrics like development estimates, earnings, and income, providing traders a extra complete outlook. Nonetheless, traders needs to be aware that analysts, like several human, can have subjective views influencing their forecasts.

Which Shares Are Analysts Recommending Now?

Benzinga Edge offers you on the spot entry to all main analyst upgrades, downgrades, and worth targets. Type by accuracy, upside potential, and extra. Click here to stay ahead of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.

Newest Rankings for ANIP

View More Analyst Ratings for ANIP

View the Latest Analyst Ratings

© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.